Kangstem Biotech Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Feb 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 22, 2027The maintenance fee for Composition for Preventing or Treating Inflammatory Diseases, Containing, as Active Ingredient, Stem Cells Overexpressing SOD3 (US 11,730,766) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
- 1 fee due Mar 22, 2027The maintenance fee for CD49F promoting proliferation, multipotency and reprogramming of adult stem cells through PI3K/AKT/GSK3 pathway (US 9,139,812) comes due Mar 22, 2027. Unpaid by Sep 22, 2027, it lapses early.
- 1 fee due Sep 22, 2027The maintenance fee for Equine amniotic fluid-derived multipotent stem cells and a method for producing the same (US 9,290,739) comes due Sep 22, 2027. Unpaid by Mar 22, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 10 of 10
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,139,812 | CD49F promoting proliferation, multipotency and reprogramming of adult stem cells through PI3K/AKT/GSK3 pathway In force · From the USPTO record | In force | From the USPTO record | |
| US 9,408,873 | Pharmaceutical composition comprising stem cells treated with NOD2 agonist or culture thereof for prevention and treatment of immune disorders and inflammatory diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 9,290,739 | Equine amniotic fluid-derived multipotent stem cells and a method for producing the same In force · From the USPTO record | In force | From the USPTO record | |
| US 9,650,604 | Equine amniotic membrane-derived mesenchymal stem cells In force · From the USPTO record | In force | From the USPTO record | |
| US 9,771,555 | Canine amniotic membrane-derived multipotent stem cells In force · From the USPTO record | In force | From the USPTO record | |
| US 11,512,285 | Method of Preparing Induced Neural Stem Cells Reprogrammed from Non-Neuronal Cells Using HMGA2 In force · High confidence | In force | High confidence | |
| US 11,730,766 | Composition for Preventing or Treating Inflammatory Diseases, Containing, as Active Ingredient, Stem Cells Overexpressing SOD3 In force · High confidence | In force | High confidence | |
| US 12,350,295 | Complex for promoting cartilage differentiation comprising cartilage cell-free crush and stem cell and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US D1,054,587 | Storage box for vial bottles In force · From the USPTO record | In force | From the USPTO record | |
| US 12,589,116 | Method for Producing Umbilcal Cord Blood-Derived Stem Cell with Enhanced Efficacy In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
13 pending · 2 abandoned · 3 no status recorded